97246 ⎘
Coordinates from 3D structures of peptides, e.g. proteins or enzymes
METHOD OF MANUFACTURING DIABETIC FOOT PATIENT-SPECIFIC DERMAL REGENERATION SHEET AND DIABETIC FOOT PATIENT-SPECIFIC DERMAL REGENERATION SHEET MANUFACTURED USING THE SAME
#2METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
#3COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3
#4MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF
#5BINDING PROTEINS AND METHODS OF USE THEREOF
#6ANTI-IL-17A ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS
#7BROADLY NEUTRALIZING ANTI-HIV ANTIBODIES AND EPITOPE THEREFOR
#8ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
#9SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY
#10Novel Antigen-Binding Chimeric Proteins and Methods and Uses Thereof
#11MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF
#12COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY
#13SUPRAMOLECULAR ASSEMBLIES, COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME
#14CRYSTAL STRUCTURE OF CRISPR CPF1
#15BINDING SITE IN TYPE 2 RYANODINE RECEPTOR
#16COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOF
#17Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation
#18VARIANT ALPHA-AMYLASES HAVING AMINO ACID SUBSTITUTIONS THAT LOWER THE PKA OF THE GENERAL ACID
#19RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE
#20Compositions and methods relating to structural determination of small proteins
#21SYSTEM AND METHOD FOR DISCOVERING DRUG ACTIVE SITE OF PROTEIN USING PATHOGENIC MUTATION
#22MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF
#23Non-LTR-retroelement reverse transcriptase and uses thereof
#24INSULIN ANALOGS
#25PRODUCTION OF PROTEIN SOLID MATERIAL
#26PHARMACEUTICAL ASSOCIATION FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF
#27NOVEL BSSL ANTIBODIES
#28COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOF
#29Structural Protein Microbody and Method for Producing Same, Method for Producing Nanofiber, and Method for Producing Protein Structure
#30METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3
#31COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3
#32CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE
#33HIV-1 neutralizing antibodies and uses thereof
#34Binding proteins and methods of use thereof
#35MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF
#36Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)
#37Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
#38Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
#39ANTIBODIES TO COAGULATION FACTOR XIA AND USES THEREOF
#40METHOD OF MANUFACTURING DIABETIC FOOT PATIENT-SPECIFIC DERMAL REGENERATION SHEET AND DIABETIC FOOT PATIENT-SPECIFIC DERMAL REGENERATION SHEET MANUFACTURED USING THE SAME
#41Protein-matrix microlens array diffraction device and method for preparing the same
#42Human CGAS-DNA complex and encoded protein
#43ANTI-HUMAN PD-1 ANTIBODY CRYSTALS AND METHODS OF USE THEREOF
#44Crystal structure of a replication protein encoded by a plasmid isolated from a multiple sclerosis patient
#45Antigen-binding chimeric proteins and methods and uses thereof
#46Humanized antibodies against CD269 (BCMA)
#47Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
#48Compositions and methods for targeted cytokine delivery
#49CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS
#50Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
#51Urea biosensors and uses thereof
#52Antibody molecules to TIM-3 and uses thereof
#53Method of residue proximity information and protein model discrimination using saturation-suppressor mutagenesis
#54Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders
#55Non-neuroinvasive viruses and uses thereof
#56Non-neuroinvasive viruses and uses thereof
#57Non-LTR-retroelement reverse transcriptase and uses thereof
#58Method of detecting TIM-3 using antibody molecules to TIM-3
#59ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
#60Nucleic acids encoding broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 ENV subunits
#61Crystal structure of the large ribosomal subunit from
#62CRYSTALLIZED OXALATE DECARBOXYLASE AND METHODS OF USE
#63Antibodies to coagulation factor XIa and uses thereof
#64CRISPR-CAS SYSTEMS, CRYSTAL STRUCTURE AND USES THEREOF
#65ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
#66Antibodies Against Human NKG2D and Uses Thereof
#67Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
#68Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
#69PHARMACEUTICAL ASSOCIATION COMPRISING A GROWTH FACTOR RECEPTOR AGONIST CONJUGATED TO A BIOACTIVE CARRIER FOR CONVERTING A NEOPLASTIC CELL INTO A NON-NEOPLASTIC CELL AND USES THEREOF
#70MUTANT POLYPEPTIDES AND USES THEREOF
#71Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
#72CRYSTAL STRUCTURE OF CRISPR CPF1
#73Insulin analogs
#74Engineering surface epitopes to improve protein crystallization
#75Antibodies Against Tissue Factor Pathway Inhibitor
#76Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
#77Method for significantly increasing lentiviral production
#78Antibody drug conjugates
#79Humanized antibodies against CD269 (BCMA)
#80Binding proteins and methods of use thereof
#81Compositions and methods for targeted cytokine delivery
#82Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
#83Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets
#84Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
#85COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOF
#86Targeting of ligand binding sites in ClfA
#87Compositions and methods for protein detection
#88Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation
#89HIV-1 neutralizing antibodies and uses thereof
#90Anti-IFNAR1 antibodies with reduced Fc ligand affinity
#91Antibodies against LIF and uses thereof
#92BROADLY NEUTRALIZING HUMAN ANTIBODY THAT RECOGNIZES THE RECEPTOR-BINDING POCKET OF INFLUENZA HEMAGGLUTININ
#93Miniature protein scaffolds and methods for use thereof
#94Nucleic acids encoding antibodies to Kallidin and des-Arg-Kallidin and host cells comprising the same
#95Crystallized oxalate decarboxylase and methods of use
#96Compounds for inducing tissue formation and uses thereof
#97Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders
#98Meditopes and meditope-binding antibodies and uses thereof
#99Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
#100Antibody Therapy for Amyloid Beta Disease
#101Crystal structure of Autolysin E, method of producing the crystal and its use in screening methods
#102Anti-IFNAR1 antibodies with reduced Fc ligand affinity
#103Antibodies against human NKG2D and uses thereof
#104Multivalent and multiepitopic antibodies having agonistic activity and methods of use
#105Alpha-amylase variants with altered properties
#106Non-neuroinvasive viruses and uses thereof
#107EPITOPES OF IL-17A AND IL-17F AND ANTIBODIES SPECIFIC THERETO
#108Mutant polypeptides and uses thereof
#109ANCESTRAL PROTEINS
#110POLYPEPTIDE FRAGMENTS COMPRISING ENDONUCLEASE ACTIVITY AND THEIR USE
#111IMMUNOGLOBULINS WITH REDUCED AGGREGATION
#112Antibodies to VLA-1
#113ANTIBODIES TO NTB-A
#114Binding proteins and methods of use thereof
#115Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
#116Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
#117Anti-IL-1beta antibodies
#118Anti-ErbB antibodies and methods of use thereof
#119Antibodies, compositions, and uses
#120Antibody molecules to TIM-3 and uses thereof
#121Nucleic acid encoding anti-IL-17A antibodies
#122Antibody molecules to TIM-3 and uses thereof
#123Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
#124Humanized antibodies against CD269 (BCMA)
#125ACTRIIA BINDING AGENTS AND USES THEREOF
#126Anti-metalloprotease antibody for diagnosis and treatment of cancers
#127Methods for treating pain using antibodies to Kallidin and des-Arg-Kallidin
#128CRISPR-Cas systems, crystal structure and uses thereof
#129Crystals of angiotensin-converting enzyme (ACE)
#130Cas9 crystals and methods of use thereof
#131Mutant polypeptides and uses thereof
#132Mutant polypeptides and uses thereof
#133Method for synthesizing cellulose in vitro
#134Na1.7 antibodies and methods of using the same
#135STING crystals and modulators
#136Antibody therapy for amyloid beta disease
#137Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
#138Antibody drug conjugates
#139Cold-adapted protease derived from PAMC 21717 and uses thereof
#140Cold-adapted protease derived from PAMC 21717 and uses thereof
#141Crystal structure of bifunctional transglycosylase PBP1b from and inhibitors thereof
#142Method of preparing a dough-based product
#143CD123 binding agents and uses thereof
#144Anti-DR5 antibodies, polynucleotides and methods
#145Alpha-amylase variants with altered properties
#146Influenza A 2009 pandemic H1N1 polypeptide fragments comprising endonuclease activity and their use
#147Crystallized oxalate decarboxylase and methods of use
#148KIR-binding agents and methods of use thereof
#149Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory
#150Human anti TSHR antibodies
#151Therapeutic compounds and methods
#152Engineered monomeric antibody fragments
#153Methods of treating an IL-17A mediated pathological condition
#154Antibodies to VLA-1
#155ENGINEERING SURFACE EPITOPES TO IMPROVE PROTEIN CRYSTALLIZATION
#156CRYSTAL STRUCTURE
#157Method for identifying compounds of therapeutic interest
#158Antibody molecules to TIM-3 and uses thereof
#159Use of antibodies for detection of IL-10
#160METHODS FOR THE HUMANIZATION OF ANTIBODIES AND HUMANIZED ANTIBODIES THEREBY OBTAINED
#161Anti-IL-17A antibodies and their uses
#162Immunological reagents and uses therefor
#163Small molecules modulator of epigenetic regulation and their therapeutic applications
#164Crystalline anti-human IL-23p19 antibodies
#165Systems and methods for identifying thermodynamically relevant polymer conformations
#166Dabigatran antidotes
#167Compositions for inhibition of quiescin sulfhydryl oxidase (QSOX1) and uses of same
#168Polypeptide fragments comprising endonuclease activity and their use
#169CRYSTAL STRUCTURE OF HCV POLYMERASE COMPLEXES AND METHODS OF USE
#170Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE)
#171Antibodies to kallidin and des-Arg-kallidin
#172Meditopes and meditope-binding antibodies and uses thereof
#173Crystallized oxalate decarboxylase and methods of use
#174Crystal
#175Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
#176Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
#177Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
#178Immunoglobulins with reduced aggregation
#179Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
#180Anti-CD154 antibodies
#181Actriia binding agents and uses thereof
#182Antibodies specific to IL-17A and IL-17F
#183Methods and compositions for inhibiting neddylation of proteins
#184GPCR comprising an IC2 insertion
#185Live attenuated replication-competent arteriviruses having decreased dub/deisgylating activity
#186Meditopes and meditope-binding antibodies and uses thereof
#187Rational design of components of the oligo-saccharyltransferase-catalysed asparagine-linked glycosylation
#188Crystal structure
#189Antibodies that specifically bind alpha toxin and methods of use
#190Ribosome structure and protein synthesis inhibitors
#191MAPKAP kinase-2 as a specific target for blocking proliferation of P53-defective
#192Structural model of G protein-coupled receptor and method for designing ligand capable of binding to G protein-coupled receptor using the structural model
#193Crystalline anti-human IL-12 antibodies
#194Anti-IL-18 antibodies and their uses
#195Anti-DR5 antibodies, polynucleotides and methods
#196Variant Beta2-microglobulin, characterization of the same and applications thereof
#197Monoclonal antibodies against frizzled
#198Human anti-KIR antibodies
#199Small molecules modulator of epigenetic regulation and their therapeutic applications
#200Regulators of MMP-9 and uses thereof
#201Antibodies to NTB-A
#202PCSK9 antagonists
#203Three-dimensional structure of complement receptor type 2 and uses thereof
#204Polynucleotides encoding for frizzled-binding agents and uses thereof
#205Three-dimensional structure of isoprene synthase and its use thereof for generating variants
#206Antibodies against tissue factor pathway inhibitor
#207Crystal structure of glutaminyl cyclase
#208KIR-binding agents and methods of use thereof
#209Method of preparing a dough-based product
#210Engineering surface epitopes to improve protein crystallization
#211Inhibitors of influenza endonuclease activity and tools for their discovery
#212ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
#213Amyloid Precursor Protein E2 Domain and Uses Thereof
#214ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
#215Crystal structure of amino terminal portion of influenza virus polymerase PA subunit and use thereof
#216Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases
#217KALLIKREIN 7 MODULATORS
#218Influenza A 2009 pandemic H1N1 polypeptide fragments comprising endonuclease activity and their use
#219Crystals of human topoisomerase II-DNA binary complex, methods for preparing the same and uses thereof
#220CYCLIC AGONISTS AND ANTAGONISTS OF C5A RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
#221STRUCTURE OF CYTOKININS AND CYTOKININ RECEPTORS, AND MODULATION OF CYTOKININ SIGNALING
#222Agents for treating disease
#223Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
#224ANTIBODIES TO CONFORMATIONALLY TRAPPED PROTEINS
#225Crystal structures of neuropilin fragments and neuropilin-antibody complexes
#226Peptides for active anti-cytokine immunization
#227Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE)
#228Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE)
#229Crystallized oxalate decarboxylase and methods of use
#230Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof
#231Meditopes and meditope-binding antibodies and uses thereof
#232METHODS AND COMPOSITIONS FOR CANCER TREATMENT RELATING TO BRCA1 BRCT DOMAIN RECOGNITION OF PHOSPHORYLATED BACH1
#233CRYSTAL STRUCTURE OF GLYPHOSATE ACETYLTRANSFERASE (GLYAT) AND METHODS OF USE
#234Anti-IL-12/IL-23 antibodies and uses thereof
#235Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
#236Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof
#237Crystalline anti-hTNFalpha antibodies
#238ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
#239Anticalins
#240GPCR comprising an IC2 insertion
#241ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
#242AX132 PCSK9 antagonists
#243Nucleic acids encoding human anti-kir antibodies
#244Recombinant soluble FC receptors
#245Screening strategies for the identification of binders
#246Crystalline anti-human IL-12 antibodies
#247ANTIBODIES TO VLA-1
#248THREE-DIMENSIONAL STRUCTURES OF TALL-1 AND ITS COGNATE RECEPTORS AND MODIFIED PROTEINS AND METHODS RELATED THERETO
#249Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
#250MUTANT RAS POLYPEPTIDE CRYSTAL
#251Structure-Based Selection and Affinity Maturation of Antibody Library
#252Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
#253Human Aadenosine receptor crystals and uses thereof
#254Peptides for active anti-cytokine immunization
#255ACTRIIA BINDING AGENTS AND USES THEREOF
#256IGA1 protease polypeptide agents and uses thereof
#257Polypeptide Fragments Comprising Endonuclease Activity and Their Use
#258GEMM RIBOSWITCHES, STRUCTURE-BASED COMPOUND DESIGN WITH GEMM RIBOSWITCHES, AND METHODS AND COMPOSITIONS FOR USE OF AND WITH GEMM RIBOSWITCHES
#259Crystals of membrane proteins
#260METHODS OF PRODUCING POLYKETIDE SYNTHASE MUTANTS AND COMPOSITIONS AND USES THEREOF
#261Monoclonal antibodies to proprotein convertase subtilisin kexin type 9 (PCSK9)
#262CRYSTAL STRUCTURE
#263Crystal structure of glutaminyl cyclase
#264ANTI-LYSOPHOSPHOLIPID ANTIBODY DESIGN USING ANTIBODY STRUCTURES
#265Crystal Structure of Aldehyde Dehydrogenase and Methods of Use Thereof
#266ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)
#267Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
#268Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
#269Isolated nucleic acid encoding an antibody which specifically binds to PCSK9 and a host cell that produces the antibody
#270Method for reducing a level of LDL-cholesterol by an antibody that specifically binds to PCSK9
#271PDK inhibitor compounds and methods of use thereof
#272Molecule
#273Binding Moieties Based On Shark IgNAR Domains
#274Immunoglobulins with reduced aggregation
#275Antibodies against tissue factor pathway inhibitor
#276Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
#277SPECIFIC BINDING PROTEINS AND USES THEREOF
#278CRYSTAL STRUCTURE OF PfA-M1 AND THE PfA-M1 Co4 COMPLEX
#279METHOD AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY AND SPECIFICITY OF METHYLTRANSFERASES
#280METHOD OF PREPARING A DOUGH-BASED PRODUCT
#281Method for identifying inhibitors of
#282Human anti TSHR antibodies
#283Antibody-Guided Fragment Growth
#284Small molecules modulator of epigenetic regulation and their therapeutic applications
#285Neutralizing anti-influenza A virus antibodies and uses thereof
#286Crystal structure of human mitoNEET protein
#287Amyloid-beta peptide crystal structure
#288Pharmaceutical being used for treating cancer and fibrosis disease and the composition and uses thereof
#289Construction and crystallization of expression system for RNA polymerase PB1-PB2 protein derived from influenza virus
#290Antibodies specific to IL-17A and IL-17F
#291Structure-based construction of human antibody library
#292RAT CATHESPIN DIPEPTIDYL PEPTIDASE I (DPPI): CRYSTAL STRUCTURE AND ITS USES
#293Crystal of a cytochrome-ligand complex and methods of use
#294Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
#295Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
#296Polynucleotides encoding humanized anti-NGF antibodies
#297RIBOSWITCHES
#298Antibodies to VLA-1
#299Antibody variants
#300CRYSTAL STRUCTURE OF TAK1-TAB1